Metomylan

Metoprolol Tartrate, the active ingredient in Metomylan, is a beta blocker presented as an oral dosage form for oral use. It is employed to lower blood pressure, relieve angina, and improve outcomes in heart failure and certain cardiac arrhythmias in adult patients.

GNH USA supplies Metomylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metomylan is a selective β1‑adrenergic blocker used in several cardiovascular conditions.

- Hypertension: reduces systolic and diastolic pressure to target levels. - Angina pectoris: decreases myocardial oxygen demand, relieving chest pain. - Post‑myocardial infarction: lowers risk of recurrent infarction and mortality. - Heart failure: improves left‑ventricular function and reduces hospitalisation. - Cardiac arrhythmias: controls ventricular rate in atrial fibrillation and other rhythm disorders.

Metomylan may cause a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common Side Effects: - Fatigue or tiredness. - Dizziness or light‑headedness, especially on standing. - Bradycardia (slow heart rate). - Cold extremities or reduced peripheral circulation. - Gastrointestinal discomfort such as nausea or abdominal pain. - Headache.

Serious or Rare Side Effects: - Severe bradycardia or heart block requiring medical attention. - Marked hypotension leading to syncope. - Bronchospasm in patients with asthma or chronic obstructive pulmonary disease. - Allergic reactions including rash, pruritus, or angioedema. - Depression or mood changes. - Worsening heart failure symptoms.

Before initiating Metomylan, clinicians should consider several safety measures.

- Heart rate monitoring: assess baseline pulse and watch for excessive slowing. - Blood pressure assessment: ensure adequate control before dose escalation. - Respiratory evaluation: avoid use in uncontrolled asthma or severe COPD. - Renal/hepatic function: adjust dose in patients with impaired clearance. - Discontinuation: taper gradually to prevent rebound hypertension or tachycardia. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Metomylan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Verapamil or diltiazem: additive negative chronotropic effect may cause severe bradycardia. - Other β‑blockers: risk of excessive β‑blockade and hypotension. - Class IA or III antiarrhythmics (e.g., quinidine, amiodarone): may precipitate heart block. - Potent CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increase metoprolol plasma levels.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect. - Diuretics: combined use can enhance hypotensive response. - Antidiabetic agents: beta‑blockade may mask hypoglycaemia symptoms. - Calcium channel blockers (non‑dihydropyridine): monitor for additive cardiac effects.